checkAd
    Startseite > Aktien > Capricor Therapeutics > Nachrichten
    Capricor Therapeutics Aktie
    5,4100
     
    USD
    +3,24 %
    +0,1700 USD
    Letzter Kurs 23:20:00 Nasdaq
    5,4100
     
    USD
    100 STK
    Geldkurs 22:02:00
    5,4300
     
    USD
    600 STK
    Briefkurs 22:02:00
    ISIN: US14070B3096 · WKN: A2PLU4 · SYM: CAPR · USA

    Neueste Nachrichten

    Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
    04.06.24 · globenewswire · Capricor Therapeutics
    Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    13.05.24 · globenewswire · Capricor Therapeutics
    Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
    09.05.24 · globenewswire · Capricor Therapeutics
    Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
    08.05.24 · globenewswire · Capricor Therapeutics
    Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13
    06.05.24 · globenewswire · Capricor Therapeutics
    Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
    24.04.24 · globenewswire · Capricor Therapeutics
    Capricor Therapeutics to Present at Upcoming Investor Conferences
    21.03.24 · globenewswire · Capricor Therapeutics
    Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
    06.03.24 · globenewswire · Capricor Therapeutics
    Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    29.02.24 · globenewswire · Capricor Therapeutics
    Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
    27.02.24 · globenewswire · Capricor Therapeutics
    Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
    22.02.24 · globenewswire · Capricor Therapeutics
    Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
    20.02.24 · globenewswire · Capricor Therapeutics